NCT01169168

Brief Summary

In this study patients with

  • primary biliary cirrhosis
  • primary sclerosing cholangitis
  • alcoholic liver cirrhosis
  • hepatitis b or C
  • Wilson's disease
  • cryptogenic cirrhosis
  • Septic Inflammatory Response Syndrome (SIRS)
  • sepsis
  • septic shock
  • patients after lysis
  • Clauss fibrinogen
  • PT-Derived fibrinogen
  • immunoturbidimetric method
  • heat-precipitated fibrinogen
  • Schulz fibrinogen The result of these tests will be correlated with laboratory values which are gathered in routine and the clinical outcomes.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2010

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 23, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 26, 2010

Completed
Last Updated

July 26, 2010

Status Verified

July 1, 2010

First QC Date

July 23, 2010

Last Update Submit

July 23, 2010

Conditions

Keywords

fibrinogenSIRSsepsisliver diseasechronic liver diseaseseptic shock

Outcome Measures

Primary Outcomes (1)

  • Fibrinogen levels from 5 test methods

    * Clauss fibrinogen * PT-Derived fibrinogen * immunoturbidimetric method * heat-precipitated fibrinogen * Schulz fibrinogen

Secondary Outcomes (5)

  • Number of bleedings

  • Number of administered fresh frozen plasma

  • Number of administered erythrocyte concentrates

  • Number of administered thrombocyte concentrates

  • mortality

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients in intensive care units of the university hospital

You may qualify if:

  • SIRS
  • sepsis
  • septic shock
  • chronicle liver disease (MELD-Score \>10)
  • patient after lysis
  • patient agrees

You may not qualify if:

  • no agreement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Johann Wolfgang Goethe University Hospital

Frankfurt am Main, Hesse, 60590, Germany

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

citrated plasma

MeSH Terms

Conditions

SepsisLiver DiseasesShock, Septic

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsDigestive System DiseasesShock

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 23, 2010

First Posted

July 26, 2010

Study Start

April 1, 2010

Last Updated

July 26, 2010

Record last verified: 2010-07

Locations